Disease-stage-specific immunometabolic remodeling in pediatric obstructive sleep apnea: a single-cell transcriptomic

Qin Yang1,2, Yunfei Cui1, Xiao Huang1

  • 1Department of Sleep Medicine Center, Shenzhen Children's Hospital, Shenzhen, 518038, China.

Insights

Enlarged adenoids in children can cause obstructive sleep apnea (OSA), impairing immunity. This study reveals disrupted cellular communication and immune cell function in severe OSA, identifying HIF1A signaling as a potential therapeutic target.

Area of Science:

  • Immunology
  • Genomics
  • Pediatrics

Background:

  • Hypertrophied adenoids in children can lead to obstructive sleep apnea (OSA), impacting growth and immunity.
  • The underlying mechanisms of adenoid pathological transformation and their immune consequences in OSA are not fully understood.

Purpose of the Study:

  • To investigate the single-cell transcriptomic and immune repertoire changes in adenoids during the progression of OSA.
  • To identify molecular pathways and cellular interactions involved in OSA-related adenoid dysfunction.

Main Methods:

  • Single-cell RNA sequencing and immune repertoire profiling of adenoids from children with varying degrees of OSA.
  • Analysis of transcriptional regulatory networks, signaling pathways (Hippo, Notch, Wnt), and intercellular communication.

Main Results:

  • Significant alterations in functional modules and transcriptional networks were observed with increasing OSA severity.
  • Severe OSA was associated with downregulated energy synthesis, compromised T-cell and B-cell immunity, and reduced antigen processing.
  • HIF1A-mediated hypoxic signaling was implicated in the downregulation of key immune components like HLA and interferon.

Conclusions:

  • The study provides a comprehensive atlas of cellular and molecular changes in adenoids associated with OSA progression.
  • Dysfunctional immune responses and impaired cell-cell communication characterize severe OSA in children.
  • Targeting HIF1A-mediated hypoxic signaling presents a potential therapeutic strategy for pediatric OSA.